Literature DB >> 29475913

Expression and Clinical Significance of Claudin-7, PDL-1, PTEN, c-Kit, c-Met, c-Myc, ALK, CK5/6, CK17, p53, EGFR, Ki67, p63 in Triple-negative Breast Cancer-A Single Centre Prospective Observational Study.

Chloe Constantinou1,2, Savvas Papadopoulos3, Eirini Karyda2, Athanasios Alexopoulos4, Niki Agnanti5, Anna Batistatou5, Haris Harisis5.   

Abstract

BACKGROUND/AIM: To explore the relationship between p53, p63, c-kit, Ki67, cMet, claudin7, CK5/6, CK17, AR, PTEN, EGFR, ALK, PDL-1 and c-MYC expression with the clinicopathological features of triple- negative breast cancer.
MATERIALS AND METHODS: Immunohistochemistry was performed in 84 triple-negative breast cancer samples.
RESULTS: A statistically significant relationship between tumour grade and claudin-7 (p=0.004) and between protein p53 and positive lymph nodes (p=0.015) was found. High expression of claudin-7 (OR=65.8, 95%CI=4.35-995.19, p-value=0.003) and low expression of c-kit (OR=0.14, 95%CI=0.025-0.793, p-value=0.026) and protein p63 (OR=0.18 95%CI=0.035-0.978, p-value=0.047) was associated with higher tumour grade. Higher AR expression (OR=13.44, 95%CI=1.28-141.56, p-value=0.031) and lower expression of CK5/6 cytokeratins was found in patients with positive lymphovascular invasion (LVI) (OR=0.072, 95%CI=0.007-0.732, p-value=0.026). Only the cell proliferation index (Ki67) has been proven to be statistically significant for disease-free survival (p-value=0.0378), and overall survival (p-value=0.0186).
CONCLUSION: High expression of claudin-7 and low expression of c-kit and protein p63 are associated with higher tumour grade. AR and CK5/6 expression seem to be important in LVI. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  ALK; AR; CK 5/6; CK17; EGFR; Ki67; PDL-1; PTEN; Triple-negative breast cancer; c-MYC; c-kit; cMet; claudin 7; p53; p63

Mesh:

Substances:

Year:  2018        PMID: 29475913      PMCID: PMC5905198          DOI: 10.21873/invivo.11238

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  53 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

Review 2.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

3.  Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features.

Authors:  V Martin; F Botta; E Zanellato; F Molinari; S Crippa; L Mazzucchelli; M Frattini
Journal:  Histol Histopathol       Date:  2012-06       Impact factor: 2.303

4.  C-kit and PDGFRA gene mutations in triple negative breast cancer.

Authors:  Yun Zhu; Yan Wang; Bing Guan; Qiu Rao; Jiandong Wang; Henghui Ma; Zhihong Zhang; Xiaojun Zhou
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

5.  Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer.

Authors:  Mevlude Inanc; Metin Ozkan; Halit Karaca; Veli Berk; Oktay Bozkurt; Ayse Ocak Duran; Ersin Ozaslan; Hulya Akgun; Fatos Tekelioglu; Ferhan Elmali
Journal:  Med Oncol       Date:  2013-12-11       Impact factor: 3.064

6.  Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array.

Authors:  Fabrice Andre; Bastien Job; Philippe Dessen; Attila Tordai; Stefan Michiels; Cornelia Liedtke; Catherine Richon; Kai Yan; Bailang Wang; Gilles Vassal; Suzette Delaloge; Gabriel N Hortobagyi; W Fraser Symmans; Vladimir Lazar; Lajos Pusztai
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

7.  Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.

Authors:  Tatsuya Yoshioka; Mitsuchika Hosoda; Mitsugu Yamamoto; Kazunori Taguchi; Kanako C Hatanaka; Emi Takakuwa; Yutaka Hatanaka; Yoshihiro Matsuno; Hiroko Yamashita
Journal:  Breast Cancer       Date:  2013-05-05       Impact factor: 4.239

8.  The DeltaNp63 proteins are key allies of BRCA1 in the prevention of basal-like breast cancer.

Authors:  Niamh E Buckley; Susan J Conlon; Karin Jirstrom; Elaine W Kay; Nyree T Crawford; Anthony O'Grady; Katherine Sheehan; Simon S Mc Dade; Ching-Wei Wang; Dennis J McCance; Patrick G Johnston; Richard D Kennedy; D Paul Harkin; Paul B Mullan
Journal:  Cancer Res       Date:  2011-03-01       Impact factor: 12.701

9.  CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer.

Authors:  Olafur Andri Stefansson; Jon Gunnlaugur Jonasson; Kristrun Olafsdottir; Holmfridur Hilmarsdottir; Gudridur Olafsdottir; Manel Esteller; Oskar Thor Johannsson; Jorunn Erla Eyfjord
Journal:  Epigenetics       Date:  2011-05       Impact factor: 4.528

10.  Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.

Authors:  Jason I Herschkowitz; Karl Simin; Victor J Weigman; Igor Mikaelian; Jerry Usary; Zhiyuan Hu; Karen E Rasmussen; Laundette P Jones; Shahin Assefnia; Subhashini Chandrasekharan; Michael G Backlund; Yuzhi Yin; Andrey I Khramtsov; Roy Bastein; John Quackenbush; Robert I Glazer; Powel H Brown; Jeffrey E Green; Levy Kopelovich; Priscilla A Furth; Juan P Palazzo; Olufunmilayo I Olopade; Philip S Bernard; Gary A Churchill; Terry Van Dyke; Charles M Perou
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

View more
  10 in total

1.  The role of Ki-67 in Asian triple negative breast cancers: a novel combinatory panel approach.

Authors:  An Sen Tan; Joe Poe Sheng Yeong; Chi Peng Timothy Lai; Chong Hui Clara Ong; Bernett Lee; Jeffrey Chun Tatt Lim; Aye Aye Thike; Jabed Iqbal; Rebecca Alexandra Dent; Elaine Hsuen Lim; Puay Hoon Tan
Journal:  Virchows Arch       Date:  2019-08-12       Impact factor: 4.064

2.  Loss of PTEN Expression, PIK3CA Mutations, and Breast Cancer Survival in the Nurses' Health Studies.

Authors:  Rulla M Tamimi; A Heather Eliassen; Tengteng Wang; Yujing J Heng; Gabrielle M Baker; Vanessa C Bret-Mounet; Liza M Quintana; Lisa Frueh; Susan E Hankinson; Michelle D Holmes; Wendy Y Chen; Walter C Willett; Bernard Rosner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-10-04       Impact factor: 4.090

3.  Determination of expression profile of p53 gene in different grades of breast cancer tissues by real time PCR.

Authors:  Haleema Sadia; Munir Ahmad Bhinder; Asma Irshad; Beenish Zahid; Rais Ahmed; Sana Ashiq; Kausar Malik; Muhammad Riaz; Tariq Nadeem; Kanwal Ashiq; Ali Akbar
Journal:  Afr Health Sci       Date:  2020-09       Impact factor: 0.927

4.  Prognostic value of an immunohistochemical signature in patients with pulmonary squamous cell carcinoma undergoing complete surgical resection.

Authors:  Chengbin Lin; Yong Xi; Hongyan Yu; Xiaohan Chen; Weiyu Shen
Journal:  J Thorac Dis       Date:  2022-02       Impact factor: 2.895

5.  Epidermal growth factor receptor (EGFR) expression in the serum of patients with triple-negative breast carcinoma: prognostic value of this biomarker.

Authors:  Rogério Agenor de Araújo; Felipe Andrés Cordero da Luz; Eduarda da Costa Marinho; Camila Piqui Nascimento; Lara de Andrade Marques; Patrícia Ferreira Ribeiro Delfino; Rafael Mathias Antonioli; Breno Jeha Araújo; Ana Cristina Araújo Lemos da Silva; Maria Luiza Gonçalves Dos Reis Monteiro; Morun Bernardino Neto; Marcelo José Barbosa Silva
Journal:  Ecancermedicalscience       Date:  2022-07-20

6.  c-Kit Induces Migration of Triple-Negative Breast Cancer Cells and Is a Promising Target for Tyrosine Kinase Inhibitor Treatment.

Authors:  José A López-Mejía; Luis F Tallabs-Utrilla; Pablo Salazar-Sojo; Jessica C Mantilla-Ollarves; Manuel A Sánchez-Carballido; Leticia Rocha-Zavaleta
Journal:  Int J Mol Sci       Date:  2022-08-05       Impact factor: 6.208

7.  MYCL promotes the progression of triple‑negative breast cancer by activating the JAK/STAT3 pathway.

Authors:  Hongnan Jiang; Xiaojun Li; Wei Wang; Yaofeng Hu; Dongliang Ren
Journal:  Oncol Rep       Date:  2022-09-30       Impact factor: 4.136

8.  Mutant p53 and Twist1 Co-Expression Predicts Poor Prognosis and Is an Independent Prognostic Factor in Breast Cancer.

Authors:  Yong-Qu Zhang; Fan Zhang; Yun-Zhu Zeng; Min Chen; Wen-He Huang; Jun-Dong Wu; Wei-Ling Chen; Wen-Liang Gao; Jing-Wen Bai; Rui-Qin Yang; Huan-Cheng Zeng; Xiao-Long Wei; Guo-Jun Zhang
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

Review 9.  Emerging clinical significance of claudin-7 in colorectal cancer: a review.

Authors:  Kun Wang; Chang Xu; Wenjing Li; Lei Ding
Journal:  Cancer Manag Res       Date:  2018-09-20       Impact factor: 3.989

Review 10.  Quadruple-negative breast cancer: novel implications for a new disease.

Authors:  Shristi Bhattarai; Geetanjali Saini; Keerthi Gogineni; Ritu Aneja
Journal:  Breast Cancer Res       Date:  2020-11-19       Impact factor: 8.408

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.